Epimacular brachytherapy for wet AMD: current perspectives

Clinical Ophthalmology

Volumn 8, Issue , 2014, Pages 1661-1670

  Casaroli Marano, Ricardo P ^a,b   Alforja, Socorro ^a   Giralt, Joan ^a   Farah, Michel E ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Combined therapy; Intravitreal therapy; Macular degeneration; Radiation; Vascular endothelial growth factor; Vitrectomy

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN;

AGE RELATED MACULAR DEGENERATION; BRACHYTHERAPY; CATARACT; CONJUNCTIVAL HEMORRHAGE; DRUG EFFICACY; DRUG SAFETY; EPIMACULAR BRACHYTHERAPY; EXUDATIVE RETINITIS; GEOGRAPHIC ATROPHY; HUMAN; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PHOTORECEPTOR; PIGMENT EPITHELIUM; RETINA NEOVASCULARIZATION; RETINOPATHY; REVIEW; RISK ASSESSMENT; RISK FACTOR; VISUAL ACUITY;

EID: 84908158650     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S46068     Document Type: Review

References (69)

1. Furtado JM, Lansingh VC, Carter MJ, et al. Causes of blindness and visual impairment in Latin America. Surv Ophthalmol. 2012;57(2):149-177.
2. Virgili G, Do DV, Bressler NM, Menchini U. New therapies for neovascular age-related macular degeneration: critical appraisal of current evidence. Acta Ophthalmol Scand. 2007;85(1):6-20.
3. Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Res. 2012; 47(4):171-188.
4. Rudnicka AR, Jarrar Z, Wormald R, Cook DG, Fletcher A, Owen CG. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology. 2012;119(3):571-580.
5. Spanish Eyes Epidemiological (SEE) Study Group. Prevalence of age-related macular degeneration in Spain. Br J Ophthalmol. 2011; 95(7):931-936.
6. Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2007;114(2): 253-262.
7. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology. 2001;108(4):697-704.
8. Friedman DS, Katz J, Bressler NM, Rahmani B, Tielsch JM. Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey. Ophthalmology. 1999;106(6):1049-1055.
9. Kawasaki R, Yasuda M, Song SJ, et al. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology. 2010;117(5):921-927.
10. Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age-related macular degeneration: emerging pathogenetic and therapeutic concepts. Ann Med. 2006;38(7):450-471.
11. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379(9827):1728-1738.
12. Biarnés M, Monés J, Alonso J, Arias L. Update on geographic atrophy in age-related macular degeneration. Optom Vis Sci. 2011;88(7): 881-889.
13. Lu M, Adamis AP. Molecular biology of choroidal neovascularization. Ophthalml Clin North Am. 2006;19(3):323-334.
14. Ferrara N, Mass RD, Campa C, Kim R. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med. 2007;58:491-504.
15. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat Mol Cell Biol. 2006; 7(5):359-371.
16. Ng EWM, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Drug Disc. 2006;5(2):123-132.
17. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26(8):859-870.
18. Rosenfeld PJ. New treatments for age-related macular degeneration. Lancet. 2007;370(9597):1479.
19. Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol. 2012;154(2):222-226.
20. De Jong PT. Age-related macular degeneration. N Engl J Med. 2006; 355(14):1474-1485.
21. Klein R, Cruickshanks KJ, Nash SD, et al. The prevalence of age-related macular degeneration and associated risk factors. Arch Ophthalmol. 2010;128(6):750-758.
22. Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol. 2010;10:31.
23. Reynolds R, Rosner B, Seddon JM. Serum lipid biomarkers and hepatic lipase gene associations with age-related macular degeneration. Ophthalmology. 2010;117(10):1989-1995.
24. Barker FM. Dietary supplementation: effects on visual performance and occurrence of AMD and cataracts. Curr Med Res Opin. 2010; 26(8):2011-2023.
25. Ratnapriya R, Chew EY. Age-related macular degeneration-clinical review and genetics update. Clin Genet. 2013;84(2):160-166.
26. DeWan A, Bracken MB, Hoh J. Two genetic pathways for age-related macular degeneration. Curr Opin Genet Dev. 2007;17(3):228-233.
27. Montezuma SR, Sobrin L, Seddon JM. Review of genetics in age related macular degeneration. Semin Ophthalmol. 2007;22(4):229-240.
28. Ding X, Patel M, Chan CC. Molecular pathology of age-related macular degeneration. Prog Retin Eye Res. 2009;28(1):1-18.
29. Tuo J, Grob S, Zhang K, Chan CC. Genetics of immunological and inflammatory components in age-related macular degeneration. Ocul Immunol Inflamm. 2012;20(1):27-36.
30. Liu MM, Chan CC, Tou J. Genetic mechanisms and age-related macular degeneration: common variants, rare variants, copy number variations, epigenetics, and mitochondrial genetics. Hum Genomics. 2012;31(6):13.
31. Seddon JM. Genetic and environmental underpinnings to age-related ocular diseases. Invest Ophthalmol Vis Sci. 2013;54(14):ORSF28-30.
32. Zarbin MA. Current concepts in the pathogenesis of age related macular degeneration. Arch Ophthalmol. 2004;122(4):598-614.
33. Zarbin MA, Rosenfeld PJ. Pathway-based therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives. Retina. 2010;30(9):1350-1367.
34. Zarbin M. Pathogenesis of age-related macular degeneration. In: Bandello F, Querques G, editors. Medical Retina. ESASO Course Series. Basel: Karger; 2012;1:125-133.
35. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age related macular degeneration. Science. 2005; 308(5720):385-389.
36. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005; 308(5720):419-421.
37. Gold B, Merriam JE, Zernant J, et al; AMD Genetics Clinical Study Group. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet. 2006;38(4):458-462.
38. Maller JB, Fagerness JA, Reynolds RC, Neale BM, Daly MJ, Seddon JM. Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet. 2007;39(10):1200-1201.
39. Sivaprasad S, Hykin P. What is new in the management of wet age-related macular degeneration? Br Med Bull. 2013;105:201-211.
40. Englander M, Kaiser PK. Combination therapy for the treatment of neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2013;24(3):233-238.
41. Stannard C, Sauerwein W, Maree G, Lecuona K. Radiotherapy for ocular tumour. Eye. 2013;27(2):119-127.
42. Silva RA, Moshfeghi AA, Kaiser PK, Singh RP, Moshfeghi DM. Radiation treatment for age-related macular degeneration. Semin Ophthalmol. 2011;26(3):121-130.
43. Kirwan JF, Constable PH, Murdoch IE, Khaw PT. Beta irradiation: new uses for an old treatment: a review. Eye. 2003;17:207-215.
44. Rombouts C, Aerts A, Beck M, et al. Differential response to acute low dose radiation in primary and immortalized endothelial cells. Int J Radiat Biol. 2013;89(10):841-850.
45. Grossniklaus HE, Martinez JA, Brown VB, et al. Immunohistochemical and histochemical properties of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol. 1992;114(4):464-472.
46. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109-122.
47. Gunduz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW. Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma. Arch Ophthalmol. 1999;117(5):609-614.
48. A prospective, randomized, double-masked trial on radiation therapy for neovascular age-related macular degeneration (RAD study). Radiation Therapy for Age-Related Macular Degeneration. Ophthalmology. 1999; 106(12):2239-2247.
49. Archambeau JO, Mao XW, Yonemoto LT, et al. What is the role of radiation in the treatment of subfoveal membranes: review of radiobiologic, pathologic, and other considerations to initiate a multimodality discussion. Int J Radiat Oncol Biol Phys. 1998;40(5):1125-1136.
50. Lambooij AC, Kuijpers RW, Mooy CM, Kliffen M. Radiotherapy of exudative age-related macular degeneration: a clinical and pathologic study. Graefes Arch Clin Exp Ophthalmol. 2001;239(7):539-543.
51. Kishan AU, Modjtahedi BS, Morse LS, Lee P. Radiation therapy for neovascular age-related macular degeneration. Int J Radiat Oncol Biol Phys. 2013;85(3):583-597.
52. Hart PM, Archer DB, Chakravarthy U. Asymmetry of disciform scarring in bilateral disease when one eye is treated with radiotherapy. Br J Ophthalmol. 1995;79(6):562-568.
53. Ivanov VN, Zhou H, Ghandhi SA, Karasic TB, Yaghoubian B, Amundson SA. Radiation-induced bystander signaling pathways in human fibroblasts: a role for interleukin-33 in the signal transmission. Cell Signal. 2010;22(7):1076-1087.
54. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study Year 1. Am J Ophthalmol. 2008;145(2):239-248.
55. Finger PT, Berson A, Ng T, Szechter A. Ophthalmic plaque radiotherapy for age-related macular degeneration associated with subretinal neovascularization. Am J Ophthalmol. 1999;127(2):170-177.
56. Jaakkola A, Heikkonen J, Tommila P, Laatikainen L, Immonen I. Strontium plaque brachytherapy for exudative age-related macular degeneration: three-year results of a randomized study. Ophthalmology. 2005;112(4):567-573.
57. Lommatzsch PK, Werschnik C, Schuster E. Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 2000;238(2):129-137.
58. Petrarca R, Jackson TL. Radiation therapy for neovascular age-related macular degeneration. Clin Ophthalmol. 2011;5:57-63.
59. Canton VM, Quiroz-Mercado H, Velez-Montoya R, et al. 24-Gy low-voltage X-ray irradiation with ranibizumab therapy for neovascular AMD: 6-month safety and functional outcomes. Ophthalmic Surg Lasers Imaging. 2012;43(1):20-24.
60. Cole CJ, Charteris DG. Cataract extraction after retinal detachment repair by vitrectomy: visual outcome and complications. Eye. 2009; 23(6):1377-1381.
61. Robison CD, Krebs I, Binder S, et al. Vitreomacular adhesion in active and end-stage age-related macular degeneration. Am J Ophthalmol. 2009;148(1):79-82.
62. Stefansson E, Landers MB 3rd, Wolbarsht ML. Increased retinal oxygen supply following pan-retinal photocoagulation and vitrectomy and lensectomy. Trans Am Ophthalmol Soc. 1981;79:307-334.
63. Jampol LM. Oxygen therapy and intraocular oxygenation. Trans Am Ophthalmol Soc. 1987;85:407-437.
64. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 1996;41(1):31-39.
65. Avila MP, Farah ME, Santos A, Duprat JP, Woodward BW, Nau J. Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration. Br J Ophthalmol. 2009;93(3):305-309.
66. Avila MP, Farah ME, Santos A, et al. Three-year safety and visual acuity results of epimacular 90 strontium/90 Yttrium brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Retina. 2012;32(1):10-18.
67. Dugel PU, Petrarca R, Bennett M, et al. Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: Twelve-month safety and efficacy results. Ophthalmology. 2012;119(7):1425-1431.
68. Petrarca R, Dugel PU, Bennett M, et al. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 24 safety and efficacy results. Retina. 2014;34(5):874-879.
69. Dugel PU, Bebchuk JD, Nau J, et al. (CABERNET Study Group). Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET). Ophthalmology. 2013;120(2):317-327.